When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Faricimab - Wikipedia

   en.wikipedia.org/wiki/Faricimab

   Faricimab, sold under the brand name Vabysmo (/ v ə ˈ b aɪ z m oʊ / və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

3. Mounjaro vs. Ozempic: Which One Is Best for Me to Try for ...

   www.aol.com/mounjaro-vs-ozempic-one-best...

   Mounjaro vs. Ozempic: Which Is Better for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. They’re both once-a-week injectable drugs designed to help patients with ...

4. Remdesivir - Wikipedia

   en.wikipedia.org/wiki/Remdesivir

   Remdesivir, sold under the brand name Veklury, [13] [15] is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. [16] It is administered via injection into a vein. [17] [18] During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous ...

5. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis Intetumumab [83] [84] mab: human: CD51: solid tumors (prostate cancer, melanoma) Inolimomab: mab: mouse: CD25 (α chain of IL-2 receptor) graft versus host disease: Inotuzumab ozogamicin [39] Besponsa: mab: humanized: CD22: Y: Acute ...

6. FDA Approves First Injectable Eye Medicine For Vision Loss ...

   www.aol.com/news/fda-approves-first-injectable...

   The FDA has approved Genentech's, a unit of Roche Holdings AG (OTC: RHHBY), Vabysmo (faricimab-svoa) for wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).

7. Ranibizumab - Wikipedia

   en.wikipedia.org/wiki/Ranibizumab

   Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.